首页|Enterovirus A71 antivirals:Past,present,and future

Enterovirus A71 antivirals:Past,present,and future

扫码查看
原文链接
  • 万方数据
  • 维普
Enterovirus A71(EV-A71)is a significant human pathogen,especially in children.EV-A71 infection is one of the leading causes of hand,foot,and mouth diseases(HFMD),and can lead to neuro-logical complications such as acute flaccid myelitis(AFM)in severe cases.Although three EV-A71 vac-cines are available in China,they are not broadly protective and have reduced efficacy against emerging strains.There is currently no approved antiviral for EV-A71.Significant progress has been made in devel-oping antivirals against EV-A71 by targeting both viral proteins and host factors.However,viral capsid inhibitors and protease inhibitors failed in clinical trials of human rhinovirus infection due to limited ef-ficacy or side effects.This review discusses major discoveries in EV-A71 antiviral development,analyzes the advantages and limitations of each drug target,and highlights the knowledge gaps that need to be addressed to advance the field forward.

Enterovirus A71EV-A71AntiviralsAcute flaccid myelitisHandFoot and mouth disease(HFMD)Picornavirus2C protein

Jun Wang、Yanmei Hu、Madeleine Zheng

展开 >

Department of Pharmacology and Toxicology,College of Pharmacy,the University of Arizona,Tucson,AZ 85721,USA

National Institute of Allergy and Infectious Diseasess of HealthNational Institute of Allergy and Infectious Diseasess of HealthNational Institute of Allergy and Infectious Diseasess of HealthNational Institute of Allergy and Infectious Diseasess of HealthArizona Biomedical Research Commission Centre Young Investigator grantArizona Biomedical Research Commission Centre Young Investigator grantNIH training

NIHUSAgrantsAI147325AI157046ADHS18-198859USAT32 GM008804

2022

药学学报(英文版)

药学学报(英文版)

CSTPCDCSCDSCI
ISSN：
年,卷(期)：2022.12(4)
  • 4
  • 226